ERNA (Ernexa Therapeutics) LT-Debt-to-Total-Asset: 0.02 (As of Mar. 2026)


ERNA Ernexa Therapeutics Inc ERNA
30 GF Score
Price $6.45
! 4 Warning Signs
View Full Analysis

What is Ernexa Therapeutics LT-Debt-to-Total-Asset?

Ernexa Therapeutics ERNA -6.48% 30 LT-Debt-to-Total-Asset is 0.02 as of Mar. 2026. GuruFocus rates ERNA with a GF Score™ of 30/100. The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Ernexa Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.02.

Ernexa Therapeutics's long-term debt to total assets ratio declined from Mar. 2025 (0.08) to Mar. 2026 (0.02). It may suggest that Ernexa Therapeutics is progressively becoming less dependent on debt to grow their business.

Ernexa Therapeutics  (NAS:ERNA) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Ernexa Therapeutics LT-Debt-to-Total-Asset Related Terms

Ernexa Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Ernexa Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ernexa Therapeutics LT-Debt-to-Total-Asset Chart

Ernexa Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.07 0.04 0.81 0.09 0.05

Ernexa Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.05 0.06 0.05 0.02
ERNA
30GF Score
Ernexa Therapeutics Inc ERNA
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ernexa Therapeutics LT-Debt-to-Total-Asset Calculation

Ernexa Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=0.277/5.834
=

Ernexa Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=0.226/10.543
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.02 mean?
Ernexa Therapeutics (ERNA) has a LT-Debt-to-Total-Asset of 0.02 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Ernexa Therapeutics and its competitors.
Is Ernexa Therapeutics' LT-Debt-to-Total-Asset too high?
Ernexa Therapeutics' current LT-Debt-to-Total-Asset is 0.02. Overall, Ernexa Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Ernexa Therapeutics' LT-Debt-to-Total-Asset compare to PMCB and SYBX?
Ernexa Therapeutics' LT-Debt-to-Total-Asset of 0.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Ernexa Therapeutics and its competitors. Ernexa Therapeutics's current LT-Debt-to-Total-Asset is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ernexa Therapeutics stock overvalued right now?
Ernexa Therapeutics (ERNA) has a current LT-Debt-to-Total-Asset of 0.02. The current LT-Debt-to-Total-Asset is 0.02. Ernexa Therapeutics' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Ernexa Therapeutics (ERNA), the current LT-Debt-to-Total-Asset is 0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ernexa Therapeutics Business Description

Address 1035 Cambridge Street, Suite 18A, Cambridge, MA, USA, 02141
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
30GF Score

Get the complete analysis for ERNA

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.45
Price